HCPLive® peer-to-peer panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's healthcare professionals.
Experts in hepatology discuss recent updates in primary biliary cholangitis (PBC) treatment and monitoring. They review recently published real-world data and share their approach to personalizing treatment and what is on the horizon for PBC care.
A panel of experts discuss the role of type 2 inflammation in asthma, challenges with long-term use of corticosteroids, and the emerging role of biologics and various mechanisms of actions in the management of asthma.
Experts discuss therapies and sequencing strategies for treating inflammatory bowel disease, highlight the efficacy and safety of these treatments, and explore prospective advances in the care of patience with inflammatory bowel disease.
Experts discuss gut microbiota, current and emerging microbiome-based therapies for C difficile, and the practical ways to incorporate these treatments into your clinical practice.
A panel of medical experts discuss the current treatment landscape surrounding atopic dermatitis.
Experts in dermatology focus on how new and advanced treatments are impacting the quality of life for individuals with atopic dermatitis (AD). They explore how to optimize the patient experience by utilizing these therapies in a strategic matter.
Experts in dermatology discuss the pathophysiology of vitiligo, current standards of care, and new and emerging therapies. They also explore evidence-based approaches and patient-centered care to manage vitiligo and improve patient outcomes.
In this upcoming program, experts discuss the importance of correct diagnosis and early treatment of rare dermatologic disorders and best practices for critical care physicians in managing these conditions.
Experts discuss several topics pertaining to dry eye disease, including challenges and unmet needs, current and emerging treatment options, and tailoring treatment strategies based on individual patient factors.
Expert retina specialists discuss long-term experience with anti-VEGF therapies for age-related macular degeneration and diabetic macular edema, and share evidence-based strategies to improve treatment outcomes.
Updates in the management of immune-mediated kidney diseases; challenges in diagnosis of immunoglobulin A nephropathy (IgAN) and C3 glomerulopathy (C3G), current management and emerging treatment options.
In this program, our expert panel discusses several topics pertaining to type 1 diabetes, including screening and diagnosis, current and emerging treatments, and the role of clinicians in early testing and patient education.
Expert dermatologists discuss 3 patient case scenarios and their approach to finding the best treatment for each patient type. They discuss data, pros and cons of use of various classes of treatments, approaches to monitoring the disease, and changing treatment based on patient and disease characteristics.
Experts in psychiatry focus on treatment options for major depressive disorder (MDD). The discussion centers on data with newer mechanisms of action, new and emerging treatment options, and management of MDD in specific patient populations and how new treatments are aiming to fulfill unmet needs in MDD.
Advanced practice providers in dermatology discuss the treatment landscape for the management of plaque psoriasis. They review available and emerging treatment options, highlighting recent approvals and long-term safety and efficacy data.
Expert dermatologists discuss diagnosis and treatment of prurigo nodularis (PN). They review data for the only FDA-approved treatment for prurigo nodularis and the implications of the results in management of the disease.
Rheumatology specialists discuss challenges in the management of rheumatoid arthritis (RA), and how the trial-and-error approach to treatment selection and continued use of ineffective treatments impacts quality of life in RA. The panel discusses tools available to guide treatment selection and how personalization of care can improve treatment outcomes.
Experts gastroenterologists share insights on optimizing the management of Crohn’s disease, focusing on the current treatment landscape and the role of biologic therapy.
Retina specialists discuss clinical burden of geography atrophy, its current management, data with emerging treatment options, and the promise newer therapies might offer for treatment of geographic atrophy.
In this upcoming HCPLive program, experts review available and emerging treatment options for the management of plaque psoriasis, highlighting recent approvals and long-term safety and efficacy data.
Key opinion leaders discuss management of attention deficit hyperactivity disorder (ADHD) in pediatric and adult population and how the emerging data are likely to influence treatment of ADHD in adult patients going forward.
Expert health professionals provide key insights on recently approved SARS-CoV-2 booster shots highlighting current recommendations and optimizing patient communication and education on vaccination options.
Experts in cardiology discuss the management of hypercholesterolemia and atherosclerotic cardiovascular diseases (ASCVD), the importance of achieving LDL-C lowering goals, and treatment of hypercholesterolemia in patients who are statin-intolerant.
An expert cardiologist, sleep specialist, and pulmonologist, share insights on the awareness and treatment of sleep disorders, including insomnia, that co-occur with other health conditions.
Experts in dermatology provide an overview of pediatric atopic dermatitis and take a deep dive into the management of this condition highlighting recent treatment advances.
Experts in blood disorders share the importance of managing red blood cell health and optimal approaches and unmet needs in the management of sickle cell disease.
Experts in dermatology discuss treatment considerations for pediatric patients with atopic dermatitis and highlight emerging therapeutics andthe role they are likely to play in the future treatment of this condition.
Dr. Feuerstadt, a gastroenterologist, discusses foundational trials and ongoing studies in the use of fecal microbial transplantation (FMT) for treatment of recurrent C. difficile infections.